An analyst from Morgan Stanley upgraded Neuropace (NASDAQ: NPCE) from 'underweight' to 'equalweight' with a price target of $6.00. Prior to this rating, Neuropace had 3 buy ratings, 1...
Investing.com - Neuropace (NASDAQ: NPCE) reported second quarter EPS of $-0.36, $0.11 better than the analyst estimate of $-0.47. Revenue for the quarter came in at $16.5M versus the...
NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker...
NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Ms. Kelley...
A Morgan Stanley analyst maintained Neuropace (NASDAQ: NPCE) at Underweight and a price target of $5.00 from a prior price target of %currency%%price%. Prior to this rating, Neuropace had...
Investing.com - Neuropace (NASDAQ: NPCE) reported first quarter EPS of $-0.41, $0.09 better than the analyst estimate of $-0.50. Revenue for the quarter came in at $14.47M versus the...
NeuroPace (NPCE) reported Q4 EPS of ($0.45), $0.05 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $12.4...
Investing.com - Neuropace (NASDAQ: NPCE) reported fourth quarter EPS of $-0.45, $0.05 better than the analyst estimate of $-0.50. Revenue for the quarter came in at $12.8M versus the...
Investing.com - Neuropace reported on Tuesday third quarter {{erl-1172579||earnings that beat analysts' forecasts and revenue that fell short of expectations. Neuropace announced earnings...
NeuroPace (NPCE) reported Q2 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $10.2 million versus the consensus estimate of $11.08...
* Major U.S. indexes fall, Nasdaq off ~1%; Russell 2000 off ~2%* Energy weakest major S&P 500 sector; utilities lead gainers* Dollar edges up; crude slumps, gold rises* U.S. 10-Year Treasury...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
